Newcastle gets £5m to boost drug development

Published: 7-Aug-2015

Programme of research projects will examine new strategies to develop medicines for cancer treatment

Cancer Research UK’s Drug Discovery Committee has awarded Newcastle University’s Northern Institute of Cancer Research £5m to bring more cancer drugs to clinical trials.

The award will be given during a five-year period and is designed to help build on Newcastle’s success in drug development. The extra money will help to fund a programme of six to eight research projects, which will examine new strategies to develop medicines for cancer treatment.

The Newcastle drug discovery unit specialises in identifying targeted drugs, which are highly selective in their ability to kill cancer cells. Steve Wedge, Professor of Stratified Cancer Medicine Discovery at Newcastle University, said: ‘This funding will allow us to investigate new approaches to target types of cancer that are difficult to treat, such as liver cancer and some cancers of the blood.’

‘Our group has an excellent track record in drug discovery, with a team of experts focused on cancer research, chemistry and structural biology. Newcastle has made significant contributions to a number of new medicines, including the first-in-class PARP inhibitor, Rucaparib, which is being tested in clinical trials for ovarian and breast cancer. PARP is an enzyme that is critical in repairing DNA damage in some tumours and by blocking its activity these cancer cells cannot mend themselves and so die,’ he added.

Dr David Scott, Cancer Research UK’s Director of Science Funding, said: ‘We’re excited to further invest in the best drug development research taking place in the UK and to build upon Newcastle’s success. The Northern Institute for Cancer Research has the expertise to develop innovative drugs that could help to save thousands of lives and we look forward to seeing the results of this extra investment.’

You may also like